According to the issuing arrangement, four new shares of Science and Technology Innovation Board will be issued soon. On December 1st, Dongxin shares and Dizhe Pharmaceuticals were issued; on December 2nd, BeiGene, Ltd. was issued; and on December 3rd, Jiahe Meikang was issued. The four new shares to be issued are expected to raise a total of 26.651 billion yuan. Dongxin shares, issued on December 1, with the application code 787110, intend to issue 111 million shares to the public, of which 15.4785 million shares will be issued online at an issue price of 30.18 yuan, with a price-to-earnings ratio of 760.38 times. The upper limit for purchase in a single account is 15000 shares. the number of shares applied for is an integral multiple of 500 shares, and Dingge is required to hold a market capitalization of 150000 yuan on the Shanghai stock market. The issuer is Chinese mainland's leading memory chip design company, focusing on the research, development, design and sales of small and medium-sized general-purpose memory chips. Chinese mainland is one of the few companies that can provide complete solutions for memory chips such as NAND, NOR and DRAM at the same time, and can provide chip customization development services for high-quality customers. The industry is the computer, communications and other electronic equipment manufacturing industry, with net profits of-63.8373 million yuan and 19.5331 million yuan in 2019 and 2020, respectively, with year-on-year changes of-192.80% and 130.60%. Dizhe Pharmaceutical, with the issuance date of December 1 and the application code 787192, intends to issue 40.0001 million shares to the public, of which 7.6 million shares will be issued online at an issue price of 52.58 yuan, with a ceiling of 7500 shares for a single account and an integral multiple of 7500 shares. Dingge is required to hold a market capitalization of 75000 yuan on the Shanghai stock market. The main business is R & D and wholesale of chemical preparations, chemical raw materials and biological drugs; technology development, technology transfer and technical services; self-operation and agency for the import and export of all kinds of commodities and technologies (except those restricted or prohibited by the state); economic and business consulting (excluding investment consulting). (projects that must be approved according to law can carry out business activities only with the approval of relevant departments) licensed projects: drug production; drug wholesale; drug retail (projects that must be approved according to law can be carried out only with the approval of relevant departments., The specific business projects shall be subject to the results of examination and approval. The industry is the pharmaceutical manufacturing industry, with net profits of-446 million yuan and-587 million yuan in 2019 and 2020, respectively, with year-on-year changes of-156.75% and-31.60%. BeiGene, Ltd., whose issue date is December 2 and the application code is 787235, plans to issue 115 million shares to the public, and is expected to raise 20.377 billion yuan, of which 33.3655 million shares will be issued online. The main business is a global, commercial biotechnology company specializing in research, development, production and commercialization of innovative drugs. The industry is the pharmaceutical manufacturing industry, with net profits of-6.915 billion yuan and-6.915 billion yuan in 2019 and 2020, respectively, with year-on-year changes of-45.67% and-64.63%. Jiahe Meikang, which will be issued on December 3 with the application code 787246, plans to issue 34.4694 million shares to the public and is expected to raise 835 million yuan, of which 9.8235 million shares will be issued online. The company is one of the earliest domestic enterprises engaged in the research and development and industrialization of medical information software, and has been ploughing the field of clinical information for a long time, and is one of the leading enterprises in this field. The industry is the software and information technology service industry, with net profits of 3.4214 million yuan and 21.2654 million yuan in 2019 and 2020, respectively, with year-on-year changes of 105.25% and 521.54%. List of new share issues abbreviated as Application Code issue date (10,000 shares) online issuance (10,000 shares) Application Price (RMB 10,000) maximum market value required for purchase (10,000 yuan) Dongxin shares 787110 2021.12.01 11056.24 1547.85 30.18 15.00 Dizhe Pharmaceutical 787192 2021.12.01 4000.01 760.00 52.58 BeiGene, Ltd. 787235 2021.12.02 11505 .53 3336.55 33.00 Jiahe Meikang 787246 2021.12.03 3446.94 982.35 9.50